Autres langues Tonix Pharmaceuticals Nasdaq

Actions

TNXP

US8902608624

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation 05/02/2024			Varia. 5j.	Varia. 1 janv.
0,3222 ^USD	-2,36%		+2,32%	-20,05%

21/07	Tonix Pharmaceuticals Holding Corp. annonce le départ à la retraite de Gregory M. Sullivan, directeur médical, effectif au 20 août 2026	CI
15/07	Tonix Pharmaceuticals fait progresser le TNX-801, son candidat vaccin vivant atténué à réplication minimale basé sur le virus de la variole équine contre le mpox	CI

Autres langues

27/07	Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
21/07	Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026
15/07	Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease
15/07	Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
13/07	Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage
13/07	Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment
13/07	Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
29/06	Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study
29/06	Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder
29/06	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
11/06	Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
08/06	Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage
08/06	Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA
08/06	Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
28/05	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
28/05	Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting
27/05	Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05	Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody
26/05	Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment
26/05	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
18/05	TNX-1500 for Prevention of Kidney Transplant Rejection and Autoimmune Disorders: 2nd Richard Slayman Clinical Xenotransplantation Workshop Presentation
15/05	TNX-4800 for the Prevention of Lyme disease in the U.S.: Global Lyme Alliance Presentation
14/05	Tonix Pharmaceuticals : May 2026 Investor Deck
14/05	Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
12/05	Tonix Pharmaceuticals to Participate in Two Investor Conferences in May